The following is an excerpt from a S-1/A SEC Filing, filed by ALGORX PHARMACEUTICALS INC on 12/30/2004.
-- Use Sections To Navigate Through The Document --
FORM S-1/A
SUBJECT TO COMPLETION, DATED DECEMBER 30, 2004
TABLE OF CONTENTS
PROSPECTUS SUMMARY
THE OFFERING
SUMMARY FINANCIAL DATA
RISK FACTORS
FORWARD-LOOKING STATEMENTS
USE OF PROCEEDS
DIVIDEND POLICY
CAPITALIZATION
DILUTION
BENEFICIAL OWNERS
SELECTED FINANCIAL DATA
MANAGEMENT'S DISCUSSION AND ANALYSIS
Liquidity and Capital Resources
Quantitative and Qualitative Disclosure About Market Risk
BUSINESS
Pain Management Market
Competition
Legal Proceedings
Employees
NAME AND TITLE
NAME AND TITLE
NAME AND TITLE
Compensation Committee Interlocks and Insider Participation
Director Compensation
Executive Compensation
COMPENSATION TABLE
OPTIONS
OPTIONS (AGGREGATE)
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
PRINCIPAL STOCKHOLDERS
BENEFICIAL OWNERS
DESCRIPTION OF CAPITAL STOCK
Transfer Agent and Registrar
UNITED STATES FEDERAL INCOME TAX CONSEQUENCES
SHARES ELIGIBLE FOR FUTURE SALE
UNDERWRITING
VALIDITY OF SECURITIES
EXPERTS
WHERE YOU CAN FIND MORE INFORMATION
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
BALANCE SHEET
INCOME STATEMENT
STOCKHOLDERS EQUITY
CASH FLOW
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
BALANCE SHEET
INCOME STATEMENT
CASH FLOW
PART II.
Item 13. Other Expenses of Issuance and Distribution
Item 14. Indemnification of Officers and Directors
Item 15. Recent Sales of Unregistered Securities
Item 16. Exhibits and Financial Statement Schedules
Item 17. Undertakings
SIGNATURES
EXHIBIT INDEX
EXHIBIT 10.12
EXHIBIT 10.13
EXHIBIT 10.16
EXHIBIT 10.17
EXHIBIT 10.18
EXHIBIT 23.1
Consent of Independent Registered Public
ALGORX PHARMACEUTICALS INC - S-1/A - 20041230 - MARKET_RISK
Quantitative and Qualitative Disclosure About
Market Risk
Our primary exposure to market risk is interest
income sensitivity, which is affected by changes in the general
level of U.S. interest rates, particularly because the
majority of our investments are in short-term marketable
securities. Due to the nature of our short-term investments, we
believe that we are not subject to any material market risk
exposure. We do not have any foreign currency or other
derivative financial instruments.
40